11.10.2023

NeoPhore presented a first disclosure of NP1867 at AACR-NCI-EORTC Conference in Boston, USA

On Saturday October 14th, at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference in Boston, USA NeoPhore presented a first disclosure of NP1867; a potent, selective, covalent small molecule inhibitor of DNA Mismatch Repair (MMR) protein PMS2. We showed, for the first time, that NP1867 functionally inhibits MMR in cells and elicits COSMIC mutational signatures consistent with MMR-deficient patient samples.

To download the poster please submit the form below.

Neophore EORTC Poster

More news

22.05.2024

NeoPhore closes oversubscribed Series B extension round with additional funding from Bristol Myers Squibb

NeoPhore closes oversubscribed Series B extension round with additional funding from Bristol Myers Squibb Additional funding will be used to explore…

11.04.2024

NeoPhore presented preclinical data from our PMS2 program at the AACR Annual Meeting, San Diego, 5 - 10 April 2024.

The NeoPhore team attended the American Association for Cancer Research Annual Meeting in San Diego, 5 - 10 April 2024. In collaboration with The…

01.02.2024

NeoPhore raises an additional £9.6m (USD $12.2m) Series B financing extension to further progress drug discovery pipeline

NeoPhore raises an additional £9.6m (USD $12.2m) Series B financing extension to further progress drug discovery pipeline • Italian investors, NE…

Contact us at info@neophore.com  |  
Call us +44 (0) 330 128 9990